Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical leader focused on pioneering therapies for immuno-inflammatory and dermatologic diseases. This page serves as the definitive source for verified news and press releases related to ACRS's research advancements, strategic partnerships, and operational developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and financial announcements. The curated collection includes updates on novel drug candidates like kinase inhibitors and antibody therapies targeting conditions with significant unmet medical needs.
All content is organized to provide clear insights into ACRS's dual-segment operations – from therapeutic innovations to contract research services. Regular updates ensure stakeholders stay informed about licensing agreements, pipeline expansions, and scientific breakthroughs without promotional bias.
Bookmark this page for streamlined access to essential Aclaris Therapeutics updates. Check back frequently for authoritative reporting on developments impacting both clinical research and investment considerations in the biopharmaceutical sector.
Aclaris Therapeutics (NASDAQ: ACRS) reported positive interim Phase 1a SAD/MAD results for its anti-TSLP/IL-4Rα bispecific antibody ATI-052 on January 6, 2026. The randomized, blinded, placebo-controlled study in healthy adults tested single doses (30, 120, 360, 720 mg) and multiple doses (240, 480 mg).
Key findings: favorable safety with no Grade 3 drug-related TEAEs or serious adverse events, predominant Grade 1 TEAEs, PK half-life ≥26 days, dose-proportional Cmax/AUC, and robust PD target inhibition including near-complete TSLP/IL-4 pathway suppression lasting ≥6 weeks at 360 mg. Company expects Phase 1b POC trials in AD and asthma in Q1 2026 and plans a Phase 2b AD trial in H2 2026.
Aclaris Therapeutics (NASDAQ: ACRS) was added to the Nasdaq Biotechnology Index (NBI), effective at the close of trading on December 19, 2025. The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and uses a modified capitalization-weighted methodology.
The company met NBI eligibility requirements, including minimum market capitalization, average daily trading volume and public company seasoning; the index is evaluated annually each December.
Aclaris Therapeutics (NASDAQ: ACRS) said CEO Dr. Neal Walker and senior leadership will join a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City.
The discussion is scheduled for Tuesday, December 2, 2025 at 11:00 AM EST. A live and archived webcast will be available on the company Events page at aclaristx.com and will remain accessible for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q3 2025 results and a corporate update highlighting clinical progress and financial position. The company posted positive Phase 2a topline and EADV presentation data for ITK/JAK3 inhibitor ATI-2138 (week 4 EASI -77%, BSA -64%, PP-NRS -45%) and plans a Phase 2 in an additional indication in H1 2026. Topline readouts for bispecific ATI-052 Phase 1a and anti-TSLP bosakitug Phase 2 are expected in early and H2 2026, respectively. Cash, cash equivalents and marketable securities were $167.2M as of Sept 30, 2025, with a runway into H2 2028. Q3 net loss widened to $14.6M.
Aclaris Therapeutics (NASDAQ: ACRS) will participate in three healthcare conferences in November 2025 with senior leadership presenting fireside chats.
Key events: Guggenheim on Nov 12, 2025 at 11:00 AM EST (Dr. Neal Walker et al.); Stifel on Nov 12, 2025 at 1:20 PM EST (Dr. Hugh Davis et al.); and Jefferies Global on Nov 17, 2025 at 2:00 PM GMT / 9:00 AM EST (Dr. Walker).
Live and archived webcasts will be available on the company Events page and accessible on the Aclaris website for at least 30 days.
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company, will host its 2025 R&D Day on October 14, 2025 in New York. The event will focus on the company's development of kinase and immune pathway inhibitor franchises for immuno-inflammatory diseases.
The presentation will feature insights from company leadership and expert speakers, including Dr. Zuzana Diamant and Dr. Michael C. Cameron. Key topics include the company's progress in developing small and large molecule candidates, their innovative discovery platform, ITK inhibition franchise, TSLP franchise development, and updates on ongoing clinical trials.
Aclaris Therapeutics (NASDAQ:ACRS) announced that additional data from its Phase 2a trial of ATI-2138 in atopic dermatitis will be presented as a late-breaking abstract at the 2025 EADV Congress in Paris. ATI-2138 is a selective oral covalent inhibitor targeting ITK and JAK3 for moderate-to-severe atopic dermatitis treatment.
The presentation, titled "Molecular and Clinical Effects of oral ATI-2138," will be delivered by Dr. Jessica Beaziz-Tordjman on September 18, 2025, at 14:15 CEST. The study's results will provide insights into the drug's effectiveness in treating moderate-to-severe atopic dermatitis patients.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in two major healthcare conferences in September 2025.
CEO Dr. Neal Walker and the senior leadership team will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3 at 1:00 PM EDT. Additionally, Dr. Walker will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on September 9 at 9:00 AM EDT. Both events will be webcast live and archived on the company's website.
Aclaris Therapeutics (NASDAQ:ACRS) reported Q2 2025 financial results and provided significant pipeline updates. The company achieved positive results in its Phase 2a trial of ATI-2138, their ITK/JAK3 inhibitor for atopic dermatitis, demonstrating strong efficacy and tolerability. Additionally, Aclaris initiated dosing in two key trials: a Phase 2 trial of bosakitug (anti-TSLP antibody) and a Phase 1a/1b program for ATI-052 (anti-TSLP/IL-4R bispecific antibody).
Financially, Aclaris reported a net loss of $15.4 million in Q2 2025, with cash reserves of $180.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second half of 2028. R&D expenses increased to $11.4 million, primarily due to expanded clinical development activities.
Aclaris Therapeutics (NASDAQ: ACRS) announced positive top-line results from its Phase 2a trial of ATI-2138, an oral inhibitor targeting ITK and JAK3, for atopic dermatitis treatment. The trial met its primary endpoint, demonstrating a favorable safety profile with no severe adverse events.
Key efficacy results showed a 60.5% mean improvement in EASI score at week 12, reaching 77.1% when excluding one outlier patient. Additionally, 62.5% of patients achieved significant itch reduction. The drug demonstrated strong pharmacodynamic results, with 90% ITK target occupancy at peak and significant downregulation of inflammatory markers.
Based on these results, Aclaris plans to advance ATI-2138's development for alopecia areata and explore additional indications. The company is also developing next-generation ITK inhibitors, with new INDs expected in 2026.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
